Judge Finds Watson Infringed Elan's Naprelan Patent
In the second round of a decade-old patent battle, a federal judge has found that Watson Pharmaceuticals Inc. willfully infringed the patent for Elan Corp.'s anti-inflammatory drug Naprelan, a patent once...To view the full article, register now.
Already a subscriber? Click here to view full article